Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation.
Pharmacological management of atrial fibrillation (AF) remains an important unmet medical need. Because available drugs for rhythm control of AF are often associated with a significant risk for development of ventricular arrhythmias or extracardiac toxicity, recent drug development has focused on agents that are atrial selective. Inhibition of the ultrarapid delayed rectifier potassium current (I(Kur)), a current exclusive to atria, is an example of an atrial-selective approach. Recent studies, however, have shown that loss-of-function mutations in KCNA5, the gene that encodes K(V)1.5, the alpha subunit of the I(Kur) channel, is associated with the development of AF and that inhibition of I(Kur) can promote the induction of AF in experimental models. Another potential atrial-selective approach has recently been identified. Experimental studies have demonstrated important atrioventricular differences in the biophysical properties of the sodium channel and have identified sodium channel blockers that can exploit electrophysiological distinctions between atria and ventricles. Atrial-selective/predominant sodium channel blockers such as ranolazine effectively suppress AF in experimental models involving canine-isolated right atrial preparations at concentrations that produce little to no effect on electrophysiological parameters in ventricular myocardium. Chronic administration of amiodarone was also found to exert atrial-selective depression of I(Na)-dependent parameters and thus to prevent the induction of AF. Ranolazine and amiodarone have in common the ability to rapidly dissociate from the sodium channel and to prolong the atrial action potential duration via inhibition of I(Kr). Our observations suggest that atrial-selective sodium channel block may be a fruitful strategy for the management of AF.
Antzelevitch
Charles
C
Masonic Medical Research Laboratory, Utica, NY, USA. ca@mmrl.edu
Burashnikov
Alexander
A
D000818:Animals; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology*; D006329:Heart Conduction System / Q000187:drug effects / Q000503:physiopathology*; D006801:Humans; D015640:Ion Channel Gating / Q000187:drug effects*; D008955:Models, Cardiovascular; D012964:Sodium / Q000378:metabolism*; D026941:Sodium Channel Blockers / Q000008:administration & dosage*; D016896:Treatment Outcome
D026941:Sodium Channel Blockers; D012964:Sodium
Circulation. 2006 May 23;113(20):2462-72
16717165
Am J Physiol. 1993 Oct;265(4 Pt 2):H1301-9
8238418
Pacing Clin Electrophysiol. 1995 Sep;18(9 Pt 1):1686-704
7491312
J Cardiovasc Pharmacol Ther. 2004 Sep;9 Suppl 1:S65-83
15378132
Circ Res. 1992 Sep;71(3):535-46
1323431
Fundam Clin Pharmacol. 1997;11(5):402-7
9342593
Circulation. 2007 Oct 9;116(15):1647-52
17804441
Am J Cardiol. 1999 Nov 4;84(9A):20R-28R
10568656
J Am Coll Cardiol. 2006 Aug 15;48(4):854-906
16904574
J Cardiovasc Pharmacol. 2008 Aug;52(2):121-8
18670368
Br J Pharmacol. 2008 Mar;153(6):1128-32
18071302
Circulation. 1995 Oct 1;92(7):1954-68
7671380
Expert Opin Investig Drugs. 2007 Apr;16(4):519-32
17371199
Circ Res. 2000 Nov 24;87(11):964-5
11090538
J Cardiovasc Electrophysiol. 2007 Dec;18(12):1313-20
17916155
J Neurosci. 2001 Dec 15;21(24):9629-37
11739573
Heart Rhythm. 2007 Jun;4(6):816-61
17556213
Ann Noninvasive Electrocardiol. 2009 Jul;14(3):290-300
19614642
Ann N Y Acad Sci. 2008 Mar;1123:105-12
18375582
J Atr Fibrillation. 2008;1(2):98-107
21057583
J Cardiovasc Pharmacol. 2008 Aug;52(2):105-20
18670369
J Cardiovasc Pharmacol. 2008 Oct;52(4):300-5
18841075
J Mol Cell Cardiol. 2001 May;33(5):923-32
11343415
Indian Pacing Electrophysiol J. 2008 Aug 01;8(3):175-81
18679523
Circ Arrhythm Electrophysiol. 2008 Apr;1(1):62-73
19808395
Am J Physiol. 1998 Nov;275(5):H1717-25
9815079
Cardiovasc Res. 2007 Jul 1;75(1):89-98
17466958
Curr Opin Cardiol. 2009 Jan;24(1):50-5
19077816
J Mol Cell Cardiol. 2002 Sep;34(9):1185-94
12392892
Cardiovasc Res. 1999 Oct;44(1):121-31
10615396
Circulation. 2007 Sep 25;116(13):1449-57
17785620
Br J Pharmacol. 2008 Aug;154(8):1619-30
18536759
Circulation. 2004 Aug 24;110(8):904-10
15302796
Nat Rev Drug Discov. 2006 Dec;5(12):1034-49
17139288
Cardiovasc Res. 1997 Jul;35(1):13-29
9302343
Circ Res. 1997 Jun;80(6):772-81
9168779
Physiol Rev. 2005 Oct;85(4):1205-53
16183911
J Cardiovasc Electrophysiol. 2006 Jun;17(6):648-54
16836716
Cardiovasc Res. 2005 Jul 1;67(1):69-76
15949471
Mol Pharmacol. 2008 Mar;73(3):940-8
18079277
N Engl J Med. 1989 Aug 10;321(6):406-12
2473403
J Atr Fibrillation. 2008 May 16;1(1):21
28496569
Heart Rhythm. 2005 Jul;2(7):758-72
15992736
Circulation. 2004 Oct 19;110(16):2299-306
15477405
Hum Mol Genet. 2006 Jul 15;15(14):2185-91
16772329
Heart Rhythm. 2008 Dec;5(12):1735-42
19084813
Prog Biophys Mol Biol. 1998;70(1):1-72
9785957
Circ Res. 1997 Dec;81(6):1045-52
9400386
J Cardiovasc Pharmacol. 2006 Jan;47(1):123-32
16424796
Am J Physiol. 1998 Jun;274(6):H1902-13
9841518
Circulation. 2004 Sep 28;110(13):1717-24
15364815
Cardiovasc Res. 2004 Apr 1;62(1):9-33
15023549
J Cardiovasc Electrophysiol. 2003 Aug;14(8):885-90
12890054
Heart Rhythm. 2008 Sep;5(9):1304-9
18774108